J 2001

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

OLSSON, AG; P PAUCIULLO; Vladimír SOŠKA; P LULEY; RE PIETERS et al.

Základní údaje

Originální název

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

Název anglicky

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

Autoři

OLSSON, AG; P PAUCIULLO; Vladimír SOŠKA; P LULEY; RE PIETERS; G BRODA a B PALACIOS

Vydání

Clin Ther, UNITED STATES, ELSEVIER, 2001, 0149-2918

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.721

Označené pro přenos do RIV

Ne

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Fluvastatin; hypercholesterolemia
Změněno: 16. 3. 2011 13:38, prof. MUDr. Vladimír Soška, CSc.

Anotace

ORIG EN

V originále

The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly

Anglicky

The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly